Control of parathyroid function in patients with a short history of hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 1, 2005, Pages 39-43

  Nishi, Hiroshi ^a   Sato, Takashi ^b   Kurihara, Toru ^b   Kurosawa, Takeshi ^b   Fukagawa, Masafumi ^a,c  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sumiyoshi Clinic Hospital   (Japan)

^c NONE   (Japan)

Author keywords

Calcium carbonate; Hemodialysis; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MALE; MANTEL HAENSZEL TEST; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM;

ADMINISTRATION, ORAL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS;

EID: 15344339637     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1774-9987.2005.00212.x     Document Type: Article

References (14)

1. Salem MM. Hyperparathyroidism in the hemodialysis populations. A survey of 612 patients. Am J Kidney Dis 1997; 29:862-5.
2. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46:1160-6.
3. Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004;8:3-32.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-18.
5. Rudnicki M, Hojsted J, Petersen LJ, Sorensen HA, Hyldstrup L, Transbol I. Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study. Nephron 1993;65:369-74.
6. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000;57:282-92.
7. Slatopolsky E, Weerts C, Norwood K et al. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989;36:897-903.
8. Fischer ER, Harris DC. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993;40:216-20.
9. Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. Nephron 1997;77:267-72.
10. Berl T, Berns AS, Huffer WE, Alfrey AC, Arnaud CD, Schrier RR. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis. Contrib Nephrol 1980;18:72-81.
11. Brickman AS, Coburn JW, Sherrard DJ, Wong EG, Norman AW, Singer FR. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy. Contrib Nephrol 1980;18:29-41.
12. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38.
13. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
14. National Kidney Foundation. National kidney foundation-kidney disease outcomes quality initiative (K/DOQI) clinical practice guidelines for bone mineral metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.